Roxatat 50 mg (Tablet)
Unit Price: ৳ 350.00 (1 x 3: ৳ 1,050.00)
Strip Price: ৳ 1,050.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Roxadustat |
| Company | Healthcare pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of symptomatic anemia associated with chronic kidney disease (CKD)
Description
- First-in-class HIF-PH inhibitor
- Orally administered
- Promotes erythropoiesis
- Increases endogenous production of erythropoietin
- Improves iron regulation
- Downregulates hepcidin
- Reduces EPO-suppressive effects of inflammation
Pharmacology
- Orally bioavailable
- Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)
- Increases endogenous erythropoietin production
- Reduces expression of hepcidin
- Improves iron availability
- Boosts hemoglobin levels
- Regulates gene expression for erythropoiesis and iron metabolism
- Induces coordinated erythropoiesis
- Maintains plasma erythropoietin levels
- Reduces dysregulation of iron metabolism associated with CKD
- Reduces cholesterol levels
Dosage & Administration
- Oral administration
- Taken three times per week
- Individualized dose for target Hb levels of 10 to 12 g/dL
- Different starting doses for patients not on erythropoiesis-stimulating agents and those switching from such agents
- Dose adjustments according to specific conditions
- Specific sequence for dose adjustments
- Guidelines for missed dose
Interaction
- Potential drug-drug interactions
- Specific interactions with phosphate binders, gemfibrozil, probenecid, and OATP1B1 or BCRP substrates
Side Effects
- Common adverse reactions include hypertension, vascular access thrombosis, diarrhea, peripheral edema, hyperkalemia, and nausea
Pregnancy & Lactation
- Contraindicated during pregnancy
- Contradicative for breastfeeding
Precautions & Warnings
- Use with caution in patients with pre-existing risk factors for thrombotic vascular events
- Caution in patients with a history of seizures
- Not to be administered in case of serious infection or liver disorder
- Not to be initiated in pregnant women
Use in Special Populations
- Not indicated in children
- Not recommended for patients with severe hepatic impairment
Overdose Effects
- Symptoms include increased heart rate and excessive hemoglobin concentration
- Treatment involves appropriate dose reduction or interruption
Therapeutic Class
- Drugs for Haemolytic Hypoplastic & Renal Anemia
Storage Conditions
- Store below 30°C
- In a cool, dry place away from light and moisture
- Keep out of the reach of children